{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:57:31Z","timestamp":1778637451786,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.drudis.2022.05.025","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T11:37:29Z","timestamp":1653737849000},"page":"2406-2410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Opioid epidemic and the urge to discover new treatment options"],"prefix":"10.1016","volume":"27","author":[{"given":"Hossein","family":"Omidian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niloofar","family":"Babanejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yadollah","family":"Omidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2022.05.025_b0005","unstructured":"Opioid Facts. The United States Department of Justice Website. Opioid Facts (justice.gov). Accessed February 10, 2022."},{"key":"10.1016\/j.drudis.2022.05.025_b0010","unstructured":"Epidemiologic Assessments of Abuse-Deterrent Formulations. American Health & Drugs Benefits Website. Epidemiologic Assessments of Abuse-Deterrent Formulations (ahdbonline.com). August 30, 2021. Accessed February 10, 2022."},{"key":"10.1016\/j.drudis.2022.05.025_b0015","doi-asserted-by":"crossref","first-page":"120481","DOI":"10.1016\/j.ijpharm.2021.120481","article-title":"Abuse-deterrent properties and cytotoxicity of poly(ethylene oxide) after thermal tampering","volume":"600","author":"Babanejad","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2022.05.025_b0020","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/17425255.2018.1546289","article-title":"Safety and performance of current abuse-deterrent formulations","volume":"14","author":"Ahmad","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.drudis.2022.05.025_b0025","unstructured":"Abuse-Deterrent Opioids-Evaluation and Labeling. Food and Drug Administration Website. Abuse-Deterrent Opioids-Evaluation and Labeling | FDA. April 2015."},{"key":"10.1016\/j.drudis.2022.05.025_b0030","unstructured":"Staffa JA. Evaluating the Impact of Abuse-Deterrent Formulations: Methodological Challenges in Postmarketing Data. 2017. PowerPoint Presentation (radars.org)."},{"key":"10.1016\/j.drudis.2022.05.025_b0035","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1097\/j.pain.0000000000000511","article-title":"A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs","volume":"157","author":"Cicero","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.drudis.2022.05.025_b0040","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/AJP.0000000000000585","article-title":"Evaluation of the relative abuse of an OROS extended-release hydromorphone HCI product: results from 3 postmarket surveillance studies","volume":"34","author":"Butler","year":"2018","journal-title":"Clin J Pain"},{"key":"10.1016\/j.drudis.2022.05.025_b0045","unstructured":"Lower Rates of Abuse With Nucynta ER vs Other ER Opioids. Clinical Pain Advisor Website. Lower Rates of Abuse With Nucynta ER vs Other ER Opioids \u2013 Clinical Pain Advisor. September 7, 2018."},{"key":"10.1016\/j.drudis.2022.05.025_b0050","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1136\/bmj.g1894","article-title":"FDA is urged to reverse its approval of new pain drug Zohydro ER","volume":"348","author":"McCarthy","year":"2014","journal-title":"Brit Med J"},{"key":"10.1016\/j.drudis.2022.05.025_b0055","unstructured":"Warning About Zohydro ER Hydrodocone Tablets. WebMD Website. Zohydro ER Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing \u2013 WebMD. April 05, 2022."},{"key":"10.1016\/j.drudis.2022.05.025_b0060","unstructured":"Drug Formulary Commission Monograph: oxycodone\/naltrexone extended-release (Troxyca\u00aeER). Government of Massachusetts Website. New Drug Review (mass.gov). March 2017."},{"key":"10.1016\/j.drudis.2022.05.025_b0065","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3109\/00952990.2016.1167215","article-title":"Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users","volume":"42","author":"Backonja","year":"2016","journal-title":"Am J Drug Alcohol Ab"},{"key":"10.1016\/j.drudis.2022.05.025_b0070","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s40261-016-0466-z","article-title":"Hydrocodone bitartrate ER (Hysingla((R)) ER): a review in chronic pain","volume":"36","author":"Dhillon","year":"2016","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.drudis.2022.05.025_b0075","unstructured":"Pharmacology\/Toxicology NDA Review and Evaluation Secondary Review. Access Data Food and Drug Administration Website. 206544Orig1s000PharmR.pdf (fda.gov). October 1, 2015."},{"key":"10.1016\/j.drudis.2022.05.025_b0080","unstructured":"Arymo ER (Morphine Sulfate)\/Extended Release Tablet. Access Data Food and Drug Administration Website. 208603Orig1s000ChemR.pdf (fda.gov). February 20, 2022."},{"key":"10.1016\/j.drudis.2022.05.025_b0085","unstructured":"Drug Formulary Commission Monograph Review: oxycodone hydrochloride (Oxaydo\u00ae). Government of Massachusetts Website. Mass.gov. December 17, 2015."},{"key":"10.1016\/j.drudis.2022.05.025_b0090","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s12325-015-0213-5","article-title":"The potential role of an extended-release, abuse-deterrent oxycodone\/acetaminophen fixed-dose combination product for the treatment of acute pain","volume":"32","author":"Pergolizzi","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.drudis.2022.05.025_b0095","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/ALN.0000000000002031","article-title":"Abuse-deterrent opioid formulations","volume":"128","author":"Litman","year":"2018","journal-title":"Anesthesiology"},{"key":"10.1016\/j.drudis.2022.05.025_b0100","unstructured":"Oxymorphone (marketed as Opana ER) Information. Food and Drug Administration Website. Oxymorphone (marketed as Opana ER) Information | FDA. February 6, 2018."},{"key":"10.1016\/j.drudis.2022.05.025_b0105","unstructured":"Clinical Pharmacology Review, Targiniq. Access Data Food and Drug Administration Website. 205777Orig1s000ClinPharmR.pdf (fda.gov). February 20, 2022."},{"key":"10.1016\/j.drudis.2022.05.025_b0110","unstructured":"FDA Briefing Document. Joint Meeting of Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee. Food and Drug Administration Website. download (fda.gov). January 15, 2020."},{"key":"10.1016\/j.drudis.2022.05.025_b0115","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.drugalcdep.2011.04.002","article-title":"Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing","volume":"118","author":"Larance","year":"2011","journal-title":"Drug Alcohol Depen"},{"key":"10.1016\/j.drudis.2022.05.025_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpain.2011.02.247","article-title":"Outcomes associated with tampering of EMBEDA\u00ae (morphine sulfate and naltrexone hydrochloride) extended-release capsules: a review of the first 12 months of postmarketing adverse event data","volume":"12","author":"Buckley","year":"2011","journal-title":"J Pain"},{"key":"10.1016\/j.drudis.2022.05.025_b0125","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5055\/jom.2010.0028","article-title":"Acute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature","volume":"6","author":"Ruan","year":"2010","journal-title":"J Opioid Manag"},{"key":"10.1016\/j.drudis.2022.05.025_b0130","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.annemergmed.2009.10.013","article-title":"Severe opioid withdrawal due to misuse of new combined morphine and naltrexone product (Embeda)","volume":"55","author":"Jang","year":"2010","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.drudis.2022.05.025_b0135","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1093\/pm\/pnaa272","article-title":"Postmarketing analysis of misuse, abuse, and diversion of Xtampza ER","volume":"21","author":"Geoffrey Severtson","year":"2020","journal-title":"Pain Med"},{"key":"10.1016\/j.drudis.2022.05.025_b0140","first-page":"935","article-title":"Blockchain in pharmaceutical life cycle management","volume":"27","author":"Omidian","year":"2022","journal-title":"Drug Discov"},{"key":"10.1016\/j.drudis.2022.05.025_b0145","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/14656566.2021.1901885","article-title":"Can NSAIDs and acetaminophen effectively replace opioid treatment options for acute pain?","volume":"22","author":"Pergolizzi","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.drudis.2022.05.025_b0150","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/npp.2017.190","article-title":"Selective adenylyl cyclase type 1 inhibitors as potential opioid alternatives for chronic pain","volume":"43","author":"Watts","year":"2018","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.drudis.2022.05.025_b0155","unstructured":"A Promising Alternative to Opioid Pain Medications. National Institute of Drug Abuse Website. A Promising Alternative to Opioid Pain Medications | National Institute on Drug Abuse (NIDA) (nih.gov). February 12, 2019."},{"key":"10.1016\/j.drudis.2022.05.025_b0160","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.tibs.2020.10.002","article-title":"The life cycle of the mu-opioid receptor","volume":"46","author":"Cuitavi","year":"2021","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.drudis.2022.05.025_b0165","doi-asserted-by":"crossref","first-page":"7157","DOI":"10.1073\/pnas.95.12.7157","article-title":"Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness","volume":"95","author":"Zhang","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2022.05.025_b0170","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1124\/jpet.109.161455","article-title":"The effect of protein kinase C and G protein-coupled receptor kinase inhibition on tolerance induced by mu-opioid agonists of different efficacy","volume":"332","author":"Hull","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2022.05.025_b0175","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1124\/mol.115.098293","article-title":"Role of G protein-coupled receptor kinases 2 and 3 in mu-opioid receptor desensitization and internalization","volume":"88","author":"Lowe","year":"2015","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.drudis.2022.05.025_b0180","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev-biochem-061620-044044","article-title":"Structural insights accelerate the discovery of opioid alternatives","volume":"90","author":"Che","year":"2021","journal-title":"Annu Rev Biochem"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622002161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622002161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:00:27Z","timestamp":1761224427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644622002161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1359644622002161"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2022.05.025","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opioid epidemic and the urge to discover new treatment options","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2022.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}